133 related articles for article (PubMed ID: 38785421)
1. Reverse transcription of HIV-1 2-LTR circle transcripts does frequently cause 3'-polypurine tract mutations implicated in dolutegravir resistance.
Dekker JG; Klaver B; Berkhout B; Das AT
J Virol; 2024 Jun; 98(6):e0033524. PubMed ID: 38785421
[No Abstract] [Full Text] [Related]
2. Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.
Dekker JG; Klaver B; Berkhout B; Das AT
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0102721. PubMed ID: 34633840
[No Abstract] [Full Text] [Related]
3. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
4. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.
Han YS; Mesplède T; Wainberg MA
Infect Genet Evol; 2016 Dec; 46():286-291. PubMed ID: 27353185
[TBL] [Abstract][Full Text] [Related]
5. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
[TBL] [Abstract][Full Text] [Related]
6. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
Mesplède T; Osman N; Wares M; Quashie PK; Hassounah S; Anstett K; Han Y; Singhroy DN; Wainberg MA
J Antimicrob Chemother; 2014 Oct; 69(10):2733-40. PubMed ID: 24917583
[TBL] [Abstract][Full Text] [Related]
7. Is resistance to dolutegravir possible when this drug is used in first-line therapy?
Mesplède T; Wainberg MA
Viruses; 2014 Aug; 6(9):3377-85. PubMed ID: 25166745
[TBL] [Abstract][Full Text] [Related]
8. [Resistance profile and genetic barrier of dolutegravir].
Llibre JM; Clotet B
Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():20-5. PubMed ID: 25858608
[TBL] [Abstract][Full Text] [Related]
9. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
10. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
11. Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.
Margot NA; Ram RR; White KL; Abram ME; Callebaut C
J Med Virol; 2019 Dec; 91(12):2188-2194. PubMed ID: 31389026
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
[TBL] [Abstract][Full Text] [Related]
13. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.
Underwood MR; Johns BA; Sato A; Martin JN; Deeks SG; Fujiwara T
J Acquir Immune Defic Syndr; 2012 Nov; 61(3):297-301. PubMed ID: 22878423
[TBL] [Abstract][Full Text] [Related]
14. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
[TBL] [Abstract][Full Text] [Related]
15. INSTIs and NNRTIs Potently Inhibit HIV-1 Polypurine Tract Mutants in a Single Round Infection Assay.
Smith SJ; Ferris A; Zhao X; Pauly G; Schneider JP; Burke TR; Hughes SH
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960770
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors.
Zhang WW; Cheung PK; Oliveira N; Robbins MA; Harrigan PR; Shahid A
J Infect Dis; 2018 Oct; 218(11):1773-1776. PubMed ID: 30010985
[TBL] [Abstract][Full Text] [Related]
17. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
[TBL] [Abstract][Full Text] [Related]
18. Low-cost urine tenofovir assay to triage dolutegravir resistance testing.
Martinson T; Nwogu-Attah J; Spinelli M; Gandhi M
Lancet HIV; 2024 May; 11(5):e282-e283. PubMed ID: 38461845
[No Abstract] [Full Text] [Related]
19. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
[TBL] [Abstract][Full Text] [Related]
20. Barrier to Resistance of Dolutegravir in Two-Drug Combinations.
Yoshinaga T; Miki S; Kawauchi-Miki S; Seki T; Fujiwara T
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]